Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SRPT Stock Forecast 2026-2027
$20.68
Current Price
$2.17B
Market Cap
Buy 7
Hold 13
Sell 5
Wall St Analyst Ratings
Distance to SRPT Price Targets
+83.8%
To High Target of $38.00
-3.3%
To Median Target of $20.00
-75.8%
To Low Target of $5.00
SRPT Price Momentum
-4.8%
1 Week Change
+23.9%
1 Month Change
-65.1%
1 Year Change
-3.9%
Year-to-Date Change
-68.1%
From 52W High of $64.80
+98.5%
From 52W Low of $10.42
📊 TOP ANALYST CALLS
Did SRPT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sarepta is one of their latest high-conviction picks.
Latest SRPT Stock Price Targets & Analyst Predictions
Based on our analysis of 44 Wall Street analysts, SRPT has a neutral consensus with a median price target of $20.00 (ranging from $5.00 to $38.00). The overall analyst rating is Buy (6.5/10). Currently trading at $20.68, the median forecast implies a -3.3% downside. This outlook is supported by 7 Buy, 13 Hold, and 5 Sell ratings.
The most optimistic forecast comes from Yanan Zhu at Wells Fargo, projecting a 83.8% upside. Conversely, the most conservative target is provided by Mitchell S. Kapoor at HC Wainwright & Co., suggesting a 75.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SRPT Analyst Ratings
7
Buy
13
Hold
5
Sell
SRPT Price Target Range
Low
$5.00
Average
$20.00
High
$38.00
Current: $20.68
Latest SRPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SRPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Sell | Reiterates | $5.00 |
| Mar 26, 2026 | Needham | Gil Blum | Underperform | Reiterates | $N/A |
| Mar 26, 2026 | Citigroup | Yigal Nochomovitz | Sell | Maintains | $13.00 |
| Mar 19, 2026 | Oppenheimer | Kostas Biliouris | Outperform | Reiterates | $37.00 |
| Mar 13, 2026 | Mizuho | Uy Ear | Outperform | Maintains | $31.00 |
| Mar 10, 2026 | Citigroup | Yigal Nochomovitz | Sell | Maintains | $9.00 |
| Mar 2, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Sell | Reiterates | $5.00 |
| Feb 27, 2026 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $38.00 |
| Jan 27, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Sell | Reiterates | $5.00 |
| Jan 23, 2026 | Wedbush | Yun Zhong | Outperform | Maintains | $34.00 |
| Jan 14, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Sell | Reiterates | $5.00 |
| Dec 9, 2025 | Wedbush | Yun Zhong | Outperform | Initiates | $32.00 |
| Nov 5, 2025 | Mizuho | Uy Ear | Outperform | Upgrade | $26.00 |
| Nov 5, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $19.00 |
| Nov 5, 2025 | Barclays | Gena Wang | Equal-Weight | Maintains | $20.00 |
| Nov 5, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $45.00 |
| Nov 4, 2025 | Baird | Brian Skorney | Neutral | Maintains | $15.00 |
| Oct 30, 2025 | Piper Sandler | Biren Amin | Neutral | Maintains | $16.00 |
| Sep 22, 2025 | BMO Capital | Kostas Biliouris | Outperform | Upgrade | $50.00 |
| Sep 15, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Reiterates | $22.00 |
Sarepta Therapeutics Inc. (SRPT) Competitors
The following stocks are similar to Sarepta based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sarepta Therapeutics Inc. (SRPT) Financial Data
Sarepta Therapeutics Inc. has a market capitalization of $2.17B with a P/E ratio of 20.0x. The company generates $2.20B in trailing twelve-month revenue with a -32.5% profit margin.
Revenue growth is -32.7% quarter-over-quarter, while maintaining an operating margin of -92.6% and return on equity of -53.5%.
Valuation Metrics
Market Cap
$2.17B
Enterprise Value
$2.35B
P/E Ratio
20.0x
PEG Ratio
-0.1x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
-32.7%
Gross Margin
+10.0%
Operating Margin
-92.6%
Net Margin
-32.5%
EPS Growth
-32.7%
Financial Health
Cash/Price Ratio
+43.3%
Current Ratio
2.3x
Debt/Equity
91.1x
ROE
-53.5%
ROA
-11.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sarepta Therapeutics Inc. (SRPT) Business Model
About Sarepta Therapeutics Inc.
What They Do
Develops precision genetic medicines for rare diseases.
Business Model
Sarepta Therapeutics generates revenue through the commercialization of its RNA-targeted therapeutics and gene therapies, specifically designed for rare diseases like Duchenne muscular dystrophy (DMD). The company offers key products such as EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, which target specific genetic mutations and provide treatment options for patients who have limited alternatives.
Additional Information
Founded in 1980 and based in Cambridge, Massachusetts, Sarepta focuses on advancing a pipeline of investigational therapies aimed at rare neuromuscular and central nervous system disorders. The company emphasizes innovative technologies like exon-skipping and gene therapy platforms, supporting both clinical research and commercial efforts to enhance patient access to their specialized treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
835
CEO
Mr. Douglas S. Ingram Esq., J.D.
Country
United States
IPO Year
1997
Website
www.sarepta.comSarepta Therapeutics Inc. (SRPT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.
Apr 20, 2026
By Ahan Chakraborty
Analyst Blog
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
Keros reshaped its finances with a Takeda deal, boosting revenue and cutting R&D ??? but does it truly reduce dilution risk as 2026 uncertainty looms?
Apr 20, 2026
By Ahan Chakraborty
Analyst Blog
KROS Rinvatercept: What to Know Before DMD Phase II Starts
KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.
Apr 20, 2026
By Ahan Chakraborty
Analyst Blog
Latest News
Quick Summary
Sarepta Therapeutics (NASDAQ: SRPT) will report Q1 2026 financial results on May 6, 2026, after market close, followed by a conference call at 4:30 p.m. E.T., available via webcast.
Why It Matters
Sarepta's upcoming financial results and conference call could significantly impact stock performance, providing insights into revenue trends and business strategy in precision genetic medicine.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sarepta Therapeutics (NASDAQ:SRPT) granted equity awards to 24 new employees as part of its 2024 Employment Commencement Incentive Plan, approved by its Board, in compliance with Nasdaq rules.
Why It Matters
Sarepta's grant of equity awards can signal growth and talent acquisition, potentially boosting investor confidence in future performance and innovation in genetic medicine.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Oncology mergers and acquisitions are increasing as major pharmaceutical firms aim to refresh their pipelines and invest in next-gen therapies amid patent expirations.
Why It Matters
Accelerating oncology M&A indicates strong demand for innovative therapies, suggesting potential growth and investment opportunities in the pharmaceutical sector amidst patent expirations.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Quick Summary
Sarepta Therapeutics (SRPT) recently reported earnings. Investors should monitor upcoming developments and market reactions for potential impacts on the stock.
Why It Matters
Sarepta's earnings report can influence stock performance, affecting investor sentiment and future price movements. Upcoming developments or guidance could drive volatility and trading decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The SPDR S&P Biotech ETF (XBI) provides equal weighting to biotech companies, allowing for balanced exposure across firms of varying sizes.
Why It Matters
The SPDR S&P Biotech ETF's equal-weight structure allows smaller biotech firms to have a significant impact on performance, potentially leading to higher volatility and unique investment opportunities.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
28 days ago
Quick Summary
Sarepta Therapeutics (NASDAQ:SRPT) shares rose about 20% in early trading after releasing initial clinical data from two siRNA programs for rare neuromuscular diseases.
Why It Matters
Sarepta's 20% stock surge signals positive investor sentiment due to promising clinical data, potentially enhancing its market position in rare disease treatments and attracting further investment.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Frequently Asked Questions About SRPT Stock
What is Sarepta Therapeutics Inc.'s (SRPT) stock forecast for 2026?
Based on our analysis of 44 Wall Street analysts, Sarepta Therapeutics Inc. (SRPT) has a median price target of $20.00. The highest price target is $38.00 and the lowest is $5.00.
Is SRPT stock a good investment in 2026?
According to current analyst ratings, SRPT has 7 Buy ratings, 13 Hold ratings, and 5 Sell ratings. The stock is currently trading at $20.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SRPT stock?
Wall Street analysts predict SRPT stock could reach $20.00 in the next 12 months. This represents a -3.3% decrease from the current price of $20.68. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sarepta Therapeutics Inc.'s business model?
Sarepta Therapeutics generates revenue through the commercialization of its RNA-targeted therapeutics and gene therapies, specifically designed for rare diseases like Duchenne muscular dystrophy (DMD). The company offers key products such as EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, which target specific genetic mutations and provide treatment options for patients who have limited alternatives.
What is the highest forecasted price for SRPT Sarepta Therapeutics Inc.?
The highest price target for SRPT is $38.00 from Yanan Zhu at Wells Fargo, which represents a 83.8% increase from the current price of $20.68.
What is the lowest forecasted price for SRPT Sarepta Therapeutics Inc.?
The lowest price target for SRPT is $5.00 from Mitchell S. Kapoor at HC Wainwright & Co., which represents a -75.8% decrease from the current price of $20.68.
What is the overall SRPT consensus from analysts for Sarepta Therapeutics Inc.?
The overall analyst consensus for SRPT is neutral. Out of 44 Wall Street analysts, 7 rate it as Buy, 13 as Hold, and 5 as Sell, with a median price target of $20.00.
How accurate are SRPT stock price projections?
Stock price projections, including those for Sarepta Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:46 PM UTC